Global X Telemedicine & Digital Health ETF (NASDAQ: EDOC)

Global X Telemedicine & Digital Health ETF (NASDAQ:EDOC), Quote.Headers.trade-ideas

Healthcare

Consumer Defensive

Consumer Cyclical

Other

Financial Services

The Fund invests at least 80 percent of its total assets, plus borrowings for investment purposes (if any), in the securities of the Solactive Telemedicine & Digital Health Index (Underlying Index) and in American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs) based on the securities in the Underlying Index. The Fund's 80 percent investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed. The Fund may lend securities representing up to one-third of the value of the Funds total assets (including the value of the collateral received).

Twist Bioscience Corp.

Doximity, Inc.

Insulet Corp

Resmed, Inc. Cdi

Hims & Hers Health Inc

Qiagen N.V.

Laboratory Corp. Of America Holdings

Quest Diagnostics Inc

Agilent Technologies Inc

Iqvia Holdings Inc

Global X Telemedicine & Digital Health ETF

Long Ideas

News

Sector ETFs

Broad U.S. Equity ETFs

New ETFs

Trading Ideas

ETFs

EDOC

TDSC

Select Sector SPDR-Consumer Discretionary

BBMC

Rarely is it a dull year in the exchange traded funds industry and 2020 was no exception. Among the many records set last year in ETF Land were closures and launches.

3 New ETFs For 2021: Rookies Ready To Come Of Age

Analyst Color

Health Care

Tech

General

Among new exchange-traded funds, there are always winners and losers on asset gathering. Then there are outright legends. This year, that group includes the Global X Telemedicine &amp; Digital Health ETF (NASDAQ: EDOC).

Real Reasons This New ETF&#39;s Success Is Credible

Biotech

LVGO

TDOC

Plenty of new exchange-traded funds are coming to market this year and many have something in common: Leverage to the coronavirus pandemic.

This Hot New ETF Will Be Just Fine After COVID-19 Is Defeated

GLBL X TELEMED DIGTL HLTH UCITS ETF

EDOC ACQUISITION CORP USD CL A ORD SHS

EDOC ACQUISITION CORP USD RED WTS

EDOC ACQUISITION CORP USD RTS TO AQQUIRE 1/10 OF CL A ORD SH

<p><a href="https://www.trade.gov/final-determinations-ad-and-cvd-investigations-aluminum-lithographic-printing-plates-china-and" title="https://www.trade.gov/final-determinations-ad-and-cvd-investigations-aluminum-lithographic-printing-plates-china-and">https://www.trade.gov/final-determinations-ad-and-cvd-investigations-aluminum-lithographic-printing-plates-china-and</a></p>


Legal

Global

KODK

'Final Determinations In The Antidumping Duty And Countervailing Duty Investigations Of Aluminum Lithographic Printing Plates From The People's Republic Of China And Japan' - Trade Administration; The Petitioner Is Eastman Kodak Company, Shares See A Pop In Volume To The Upside

<p>Melius Research  analyst Karen Short   initiates coverage on Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Hold rating and announces Price Target of $19.</p>


Price Target

Initiation

Analyst Ratings

Melius Research Initiates Coverage On Albertsons Companies with Hold Rating, Announces Price Target of $19

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>United Rentals</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with URI, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 12 uncommon options trades for United Rentals.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 33% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $353,700, and 8 are calls, for a total amount of $399,909.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $690.0 to $900.0 for United Rentals during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for United Rentals options trades today is 21.86 with a total volume of 342.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for United Rentals's big money trades within a strike price range of $690.0 to $900.0 over the last 30 days.</p>
<h3>United Rentals Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727112652_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>URI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$15.8</td>
<td>$13.3</td>
<td>$15.8</td>
<td>$770.00</td>
<td>$188.0K</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>URI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$85.4</td>
<td>$84.5</td>
<td>$84.5</td>
<td>$840.00</td>
<td>$67.6K</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>URI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$41.1</td>
<td>$39.8</td>
<td>$41.1</td>
<td>$820.00</td>
<td>$65.4K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">73</td>
</tr>
<tr>
<td>URI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$60.9</td>
<td>$59.0</td>
<td>$60.95</td>
<td>$900.00</td>
<td>$60.9K</td>
<td style="text-align: right;">74</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>URI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$63.0</td>
<td>$59.5</td>
<td>$60.74</td>
<td>$900.00</td>
<td>$60.7K</td>
<td style="text-align: right;">74</td>
<td style="text-align: right;">51</td>
</tr>
</tbody>
</table>
</p>
<h3>About United Rentals</h3>
<p>United Rentals is the world's largest equipment rental company. It principally operates in the United States and Canada, where it commands approximately 15% share in a highly fragmented market. It serves three end markets: general industrial, commercial construction, and residential construction. Like its peers, United Rentals historically has provided its customers with equipment that was intermittently used, such as aerial equipment and portable generators. As the company has grown organically and through hundreds of acquisitions since it went public in 1997, its catalog (fleet size of $21 billion) now includes a range of specialty equipment and other items that can be rented for indefinite periods.</p>
<p>After a thorough review of the options trading surrounding United Rentals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of United Rentals</h3>
<ul>
<li>With a volume of 96,527, the price of URI is up 1.41% at $794.66. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 30 days.</li>
</ul>
<h3>What The Experts Say On United Rentals</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $940.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on United Rentals with a target price of $940. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for United Rentals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

A Closer Look at United Rentals's Options Market Dynamics

<p>High-rolling investors have positioned themselves bearish on Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SAVA often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 37% bullish and 62% bearish. Among all the options we identified, there was one put, amounting to $98,750, and 7 calls, totaling $275,738.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $60.0 for Cassava Sciences over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cassava Sciences's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cassava Sciences's significant trades, within a strike price range of $10.0 to $60.0, over the past month.</p>
<h3>Cassava Sciences Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727112647_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$3.95</td>
<td>$10.00</td>
<td>$98.7K</td>
<td>12.7K</td>
<td style="text-align: right;">295</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.0</td>
<td>$10.7</td>
<td>$11.0</td>
<td>$60.00</td>
<td>$55.0K</td>
<td>755</td>
<td style="text-align: right;">84</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$10.75</td>
<td>$9.7</td>
<td>$10.1</td>
<td>$40.00</td>
<td>$50.5K</td>
<td>390</td>
<td style="text-align: right;">53</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$11.6</td>
<td>$10.6</td>
<td>$10.8</td>
<td>$35.00</td>
<td>$49.6K</td>
<td>4.3K</td>
<td style="text-align: right;">76</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.9</td>
<td>$6.9</td>
<td>$6.94</td>
<td>$60.00</td>
<td>$34.7K</td>
<td>1.4K</td>
<td style="text-align: right;">62</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cassava Sciences</h3>
<p>Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.</p>
<p>Following our analysis of the options activities associated with Cassava Sciences, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Cassava Sciences</h3>
<ul>
<li>Currently trading with a volume of 1,372,927, the SAVA's price is down by -10.7%, now at $26.59. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 43 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cassava Sciences options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


SAVA

Cassava Sciences Unusual Options Activity For September 23

<p>High-rolling investors have positioned themselves bullish on On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ONON often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 29 options trades for On Holding. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 51% bullish and 34% bearish. Among all the options we identified, there was one put, amounting to $126,351, and 28 calls, totaling $1,330,891.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $60.0 for On Holding over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in On Holding's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to On Holding's substantial trades, within a strike price spectrum from $25.0 to $60.0 over the preceding 30 days.</p>
<h3>On Holding 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727112640_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ONON</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$13.05</td>
<td>$12.85</td>
<td>$13.05</td>
<td>$55.00</td>
<td>$140.9K</td>
<td style="text-align: right;">776</td>
<td style="text-align: right;">784</td>
</tr>
<tr>
<td>ONON</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$3.1</td>
<td>$2.95</td>
<td>$2.97</td>
<td>$52.50</td>
<td>$126.3K</td>
<td style="text-align: right;">605</td>
<td style="text-align: right;">426</td>
</tr>
<tr>
<td>ONON</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$15.25</td>
<td>$12.85</td>
<td>$13.05</td>
<td>$55.00</td>
<td>$99.4K</td>
<td style="text-align: right;">776</td>
<td style="text-align: right;">674</td>
</tr>
<tr>
<td>ONON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.3</td>
<td>$2.28</td>
<td>$2.28</td>
<td>$55.00</td>
<td>$68.3K</td>
<td style="text-align: right;">718</td>
<td style="text-align: right;">422</td>
</tr>
<tr>
<td>ONON</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$15.35</td>
<td>$12.85</td>
<td>$12.85</td>
<td>$55.00</td>
<td>$68.0K</td>
<td style="text-align: right;">776</td>
<td style="text-align: right;">497</td>
</tr>
</tbody>
</table>
</p>
<h3>About On Holding</h3>
<p>On Holding AG is a premium performance sports brand rooted in technology, design, and impact. Its shoes, apparel, and accessories products are designed predominantly for athletic use, casual, or leisure purposes. It does not manufacture the products or the raw materials and relies instead on third-party suppliers and contract manufacturers. Geographically, it derives a majority of its revenue from the Americas and rest from Europe, Middle East and Africa, and Asia-Pacific region.</p>
<p>After a thorough review of the options trading surrounding On Holding, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of On Holding</h3>
<ul>
<li>With a trading volume of 2,098,886, the price of ONON is up by 1.98%, reaching $50.94.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 50 days from now.</li>
</ul>
<h3>What The Experts Say On On Holding</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $55.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on On Holding with a target price of $59.<br />
&#x2A; An analyst from HSBC has revised its rating downward to Hold, adjusting the price target to $52. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for On Holding, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


ONON

On Holding Options Trading: A Deep Dive into Market Sentiment

WIIM

MKFG

Markforged Holding shares are trading higher after the company announced that it has entered into a Settlement and Patent License Agreement in connection with the patent infringement litigation brought by Continuous Composites.

<p>Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 9.08% on an annualized basis producing an average annual return of 23.07%. Currently, Cencora has a market capitalization of $44.71 billion. </p>
<p><strong>Buying $1000 In COR:</strong> If an investor had bought $1000 of COR stock 5 years ago, it would be worth <strong>$2,786.77</strong> today based on a price of $228.11 for COR at the time of writing.</p>
<h3>Cencora's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727112615_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $1000 Invested In Cencora 5 Years Ago Would Be Worth Today

<p>Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) has outperformed the market over the past 5 years by 5.52% on an annualized basis producing an average annual return of 19.51%. Currently, Intuit has a market capitalization of $179.40 billion. </p>
<p><strong>Buying $100 In INTU:</strong> If an investor had bought $100 of INTU stock 5 years ago, it would be worth <strong>$237.93</strong> today based on a price of $641.74 for INTU at the time of writing.</p>
<h3>Intuit's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727112610_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


INTU

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today

<p><strong>Warner Bros. Discovery</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wbd#NASDAQ">WBD</a>) is one of the world&#39;s biggest names when it comes to entertainment. Although it has overall been a bad year for the company&#39;s stock price, positive news has allowed shares to recover.</p>
<p>On September 12th, the company announced a multi-year deal with one of the largest U.S. cable TV companies, <strong>Charter Communications</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chtr#NASDAQ">CHTR</a>), also known as Spectrum. Since the announcement, shares have been up 21%. Let&#39;s dive deeper into what the announcement means for Warner Bros.&#39;s long-term future&nbsp;and whether it can further reignite its shares.</p>
<h2><strong>Breaking Down Warner and Charter&#39;s Big Deal</strong></h2>
<p>The first notable point to make about the deal was that it was reached &quot;nearly one year early.&quot; This shows the two firms understand the need to move quickly in this space. Nielsen data shows that, in June, streaming hit a record market share in TV viewing.</p>
<p>Of the total time spent watching TV, 40.3% was through streaming services, an increase from 37.7% in Jun. 2023. Streaming increased its share mostly by taking from cable providers, whose share went from 30.6% to 27.2%.</p>
<p>Clearly, cable still has a place in the TV market, but it is slowly dying. One good thing about the deal between Warner and Charter is that it focuses on both cable and streaming. This allows the firms to look toward the future with streaming while also maintaining a solid base of customers who still prefer cable.</p>
<p>The deal gives Spectrum customers the ad-supported versions of Warner&#39;s HBO Max and Discovery+ streaming services at no extra charge. It also maintains the availability of Warner&#39;s cable channels like TNT, CNN, and the Food Network. Warner will be receiving higher fees going forward for all its cable channels except for TNT. Management actually saw the lack of a fee cut for TNT as a win since the network lost its rights to broadcast NBA games.</p>
<p>This is key as its &quot;networks&quot; segment is its largest revenue stream and most profitable segment. The network segment&#39;s 43% earnings before interest, taxes, depreciation, and amortization (EBITDA) margin over the last twelve months is strong. It far exceeds the streaming segment&#39;s figure by less than one percent.</p>
<p>Charter is planning to fully launch its direct-to-consumer (DTC) distribution to its cable customers in 2025. This could allow Warner to increase its subscribers by tapping into Charter&#39;s cable customers. HBO Max will be a &quot;preferred partner&quot; for Charter, presumably putting the app in the spotlight when it comes to marketing its DTC platform.</p>
<h2><strong>Taking the Good With the Bad</strong></h2>
<p>There are reasons to be excited, and reasons to not be so excited, about the deal. Charter reached a similar deal with Walt Disney Co.&nbsp;to carry the firm&#39;s ad-supported Disney+ service at no extra cost in January. Yet, reportedly only 10% of Charter&#39;s Select TV customers have signed up for the offer after it has been available for over six months.</p>
<p>This shows either a significant lack of interest from Charter&#39;s customer base and/or its lack of marketing of the product. However, it is apparently fixing issues that may have contributed to the lack of uptake. As Charter irons out problems with the service, Warner should benefit from Disney&#39;s use as a guinea pig.</p>
<p>Still, Charter is losing cable subscribers, making the deal less beneficial to Warner the more those losses continue. It lost 408,000 cable subscribers in Q2, a loss that more than doubled from the same period last year. For Warner and Charter&#39;s sake, hopefully the further inclusion of streaming services in cable packages can help stem these losses.</p>
<h2><strong>A Likely Step in the Right Direction, But Not Proven Yet</strong></h2>
<p>Overall, it feels too early to say that this deal will fully reignite Warner Bros.&#39;s shares. The increased fees for TV networks should help bolster profitability in that area, creating some stability. However, Warner&#39;s streaming services must boost their profits. Their EBITDA fluctuates between slightly positive and slightly negative each quarter.</p>
<p>The deal should help with that immediately, as the company can leverage Charter&#39;s reach and marketing efforts. Disney saw its streaming service have its first profitable quarter in the same quarter its agreement with Charter began.</p>
<p>However, these streaming businesses will need to demonstrate stronger uptake to prove these deals are driving significant growth.</p>
<p>The article &quot;<a href="https://www.nasdaq.com/articles/warner-bross-new-deal-spark-it-needs-reignite-shares">Is Warner Bros.&#39;s New Deal the Spark It Needs to Reignite Shares?</a>&quot; first appeared on MarketBeat.</p>


Earnings

Entertainment

Large Cap

Management

CHTR

Is Warner Bros.'s New Deal the Spark It Needs to Reignite Shares?

<p>Oppenheimer  analyst Leland Gershell   reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Outperform and maintains $15 price target.</p>


Reiteration

CAPR

Oppenheimer Reiterates Outperform on Capricor Therapeutics, Maintains $15 Price Target

<p>Melius Research  analyst Karen Short   initiates coverage on Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Hold rating and announces Price Target of $55.</p>


Melius Research Initiates Coverage On Kroger with Hold Rating, Announces Price Target of $55

<p>B of A Securities  analyst Lucy Yu   downgrades MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) from Buy to Underperform.</p>


Downgrades

MNSO

B of A Securities Downgrades MINISO Group Holding to Underperform

<h4><strong>Key Takeaways:</strong></h4>
<ul>
<li>Transsion&rsquo;s CFO was detained early this month and later released, though investors remain wary due to the company&rsquo;s thin profit margins and ongoing legal disputes</li>
<li>The smartphone maker&rsquo;s revenue rose 38% to 34.6 billion yuan in the first half of this year, with 35.7% profit growth, mostly on its expansion into new markets</li>
</ul>
<p>By Hugh Chen</p>
<p>It&rsquo;s known as the &ldquo;King of Africa&rdquo; for its status as the continent&rsquo;s leading smartphone maker. But a recent drama involving&nbsp;<strong>Transsion Holdings</strong>&nbsp;(688036.SH) has move the spotlight back to the company&rsquo;s home base in China.</p>
<p>The tense times began around two weeks ago, when CFO Xiao Yonghui was detained on suspicion of unspecified illegal activity,&nbsp;<a href="http://www.sse.com.cn/disclosure/listedinfo/announcement/c/new/2024-09-07/688036_20240907_RYQN.pdf">the company said</a>&nbsp;in a statement dated Sept. 7. But the drama abruptly ended last week when Transsion provided&nbsp;<a href="http://www.sse.com.cn/disclosure/listedinfo/announcement/c/new/2024-09-18/688036_20240918_VIJF.pdf">an update</a>&nbsp;saying Xiao had been released and resumed his duties as CFO.</p>
<p>Such disappearances aren&rsquo;t unheard of in China, and usually occur when company officials are suspected of wrongdoing or are assisting in investigations of other people suspected of crimes. Gaming company DouYu (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/doyu#NASDAQ">DOYU</a>) and private equity firm China Renaissance (1911.HK) have each lost their top executives to such circumstances over the last two years, with devastating consequences for their stocks.</p>
<p>While both executives remain out of sight, and DouYu&rsquo;s has been charged with a crime, Transsion appears to have dodged a bullet with Xiao&rsquo;s release. Still, the crisis has taken some of the momentum away from company&rsquo;s rapid rise that saw it break into the top five global smartphone makers last year as it expanded beyond its African base.</p>
<p>There&rsquo;s always the potential for future investigations, and Transsion is facing separate headaches from other legal disputes over intellectual property rights and intensifying competition. Both Chinese and international rivals are now vying for market share not only in Transsion&rsquo;s African stronghold, but also in new markets like Latin America, where the company has been expanding.</p>
<p>In its Sept. 7 statement, when Transsion first disclosed Xiao&rsquo;s detention, the company assured investors that &ldquo;current production, operations, and management remain normal,&rdquo; a position it reiterated in last week&rsquo;s announcement. Xiao was detained on Sept. 6 in Dandong, a city in Northeast China&rsquo;s Liaoning province on the border with North Korea. The company has not provided any details about the nature of his suspected illegal activity that led to the detention.</p>
<p>Unlike CFOs at many young Chinese tech companies that often jump from firm to firm after just a few years at a company, Xiao, 55, has been with Transsion for a decade after joining in 2014. He and Transsion founder Zhu Zhaojiang previously worked at Ningbo Bird, one of China&rsquo;s early smartphone leaders. Beyond this basic information, details about Xiao&rsquo;s role in Transsion are scarce.</p>
<p>Despite Transsion&rsquo;s reassurances, investors were unsettled by the developments involving Xiao. When his detention was first announced, Transsion&rsquo;s stock plunged 8% when the market opened on Sept. 9 and later closed down 5%. The stock recovered following Xiao&rsquo;s release, but investor confidence towards the company remains fragile.</p>
<p>Transsion&rsquo;s shares have been on a downward trajectory since mid-April. Last Friday&rsquo;s closing price of 84 yuan is down more than 30% from the 120 yuan recorded in mid-April. While the stock trades on China&rsquo;s domestic A-shares market, it is also accessible to international investors through a program linking the Shanghai and Hong Kong stock exchanges.</p>
<p>Transsion currently trades at a price-to-earnings (P/E) ratio of 18, which is below the 24 for rival&nbsp;<strong>Xiaomi</strong>&nbsp;(1810.HK), which is also expanding into markets where Transsion operates. Both figures are significantly lower than&nbsp;<strong>Apple&rsquo;s</strong>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) P/E ratio of 35, reflecting investors&rsquo; willingness to award higher valuations to premium market leaders with higher profit margins.</p>
<h3><strong>Mounting Challenges</strong></h3>
<p>Founded in 2006, Transsion started selling its smartphones in Africa, where it quickly gained prominence. Its Tecno, Itel, and Infinix brands have become household names across the continent. However, as market saturation and competition intensify there, Transsion has&nbsp;<a href="https://thebambooworks.com/transsion-climbs-global-smartphone-leader-board-with-its-move-out-of-africa/">started expanding</a>&nbsp;into other developing markets as well.</p>
<p>The company&rsquo;s revenue rose by 38% to 34.6 billion yuan ($4.9 billion) in the first half of this year, while its net profit increased by a similar 35.7% to 2.85 billion yuan, its latest financial results showed. The company attributed the strong performance to &ldquo;continuous expansion into emerging markets and advancement of product upgrades.&rdquo;</p>
<p>The highly competitive India market has been one of Transsion&rsquo;s recent focuses. Despite gradual gains since its relatively early entry there in 2015, the company is still trying to break into the top five vendors. Transsion has also been rapidly expanding into Southeast Asia, Eastern Europe, and Latin America. In Southeast Asia alone, it shipped 4.2 million smartphones in the first quart of 2024, triple its shipments a year earlier, according to Canalys..</p>
<p>Given those gains and its strong double-digit revenue and profit growth, why aren&rsquo;t investors more enthusiastic about this company? Two main reasons appear to underpin their concern. First, Transsion&rsquo;s low-end models typically have thin profit margins and rely on high-volume sales to boost profits. Its focus on such cheaper models has confined the company mostly to emerging markets, and kept it away from higher margin markets like Europe.</p>
<p>Transsion has also ventured into the relatively premium segment with models like the Tecno Phantom V Flip and Phantom V Fold, priced significantly higher than its traditional $100-$200 offerings. But that segment is also fiercely competitive, with rivals such as Xiaomi,&nbsp;<strong>Oppo</strong>, and&nbsp;<strong>Vivo</strong>&nbsp;already dominating markets like Southeast Asia and Latin America for such models.</p>
<p>The second, and perhaps more critical, reason for investor wariness is ongoing litigation against Transsion outside China. In July, U.S. chip giant Qualcomm filed lawsuits alleging patent infringement against the company and its subsidiaries in India, Germany, and other locations. All these cases are still pending.</p>
<p>A similar case involving Oppo highlights the negative impact such disputes can have on a company. In 2021, a Nokia lawsuit forced Oppo to withdraw from Germany entirely. Though Oppo later returned in 2023 after settling the lawsuit, its absence from one of Europe&rsquo;s largest markets cost it dearly in sales and market presence.</p>
<p>Transsion can hardly afford such setbacks and must continue proving it can gain market share in new regions to keep investors happy. At the same time, it can&rsquo;t neglect its African stronghold, especially as competitors like Xiaomi actively expand there. Its shipments in Africa grew by just 1% in the second quarter, while Xiaomi, realme, and Oppo grew by 45%, 137%, and 39%, respectively, according to Canalys.</p>
<p>The CFO crisis appears to be resolved by now, though it could still point to future legal issues for Transsion. At the same time, the ongoing patent lawsuits remain a major issue dogging the company. Addressing those concerns will be crucial for Transsion to keep up its momentum, as rivals like Xiaomi and Oppo nip at its heels in Africa and try to slow its rise in other emerging markets.</p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.</em></p>


AAPL

DOYU

Transsion Dodges Bullet With CFO's Release After Two-Week Detention

<p>Melius Research  analyst Karen Short   initiates coverage on Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Hold rating and announces Price Target of $85.</p>


Melius Research Initiates Coverage On Dollar Gen with Hold Rating, Announces Price Target of $85

<p><strong>Mullen Automotive, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares are trading lower on Monday. The company disclosed that its subsidiary, Bollinger Motors, achieved a milestone on September 20, 2024, by producing the first customer-ready <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40980994/mullen-subsidiary-bollinger-motors-achieves-major-milestone-today-with-production-of-first-custome" rel="noreferrer noopener">B4 electric truck in Livonia, Michigan</a>.</p>
<p>Bollinger Motors has partnered with Roush Industries for B4 production, utilizing Roush&#8217;s contract manufacturing services at its Livonia, Michigan facility.</p>
<p>This collaboration leverages Roush&#8217;s expertise in production and e-mobility, developed over 50 years of engineering, testing, prototyping, and manufacturing.</p>
<p>Bollinger, founder of Bollinger Motors said, &#8220;We&#8217;ve made an impact here in Detroit and I am proud of all the work this team has done to get to this day. We are launching a world-class electric truck that will be a leader in the commercial fleet business.&#8221;</p>
<p>Bollinger Motors&#8217; CEO Jim Taylor stated, &#8220;The commercial vehicle segment is ready for electrification and Bollinger Motors has developed a world-class truck that will meet the fleet needs for companies across the country. We are excited to see these vehicles roll off the line, head to dealer lots and find a home with our customers.&#8221;</p>
<p>Bollinger&#8217;s original vision in 2015 focused on launching high-end, all-electric pickup trucks and SUVs. However, recognizing that the electric SUV and pickup markets weren&#8217;t fully ready for consumers, Bollinger and his team pivoted in 2022 to develop the Class 4 all-electric truck, the Bollinger B4.</p>
<p>Notably, Bollinger Motors recently&nbsp;announced the&nbsp;2025 Bollinger B4 Chassis Cab electric truck will have a manufacturer&#8217;s <a target="_blank" href="https://www.benzinga.com/news/24/09/40921203/whats-happening-with-mullen-automotive-stock-after-reverse-split" rel="noreferrer noopener">suggested retail price (MSRP)&nbsp;of $158,758</a>.</p>
<p>Last week, the company announced an update on Volt Mobility&#8217;s recently placed $210 million commercial&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40961594/mullen-automotive-gears-up-210m-ev-deal-in-dubai-delivers-first-units-to-volt-mobility" rel="noreferrer noopener">Class 1 and Class 3 EV order in Dubai</a>.&nbsp;</p>
<p><strong>Price Action:</strong> MULN shares are down 8.5% at $6.11&nbsp;at the last check Monday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says" target="_blank" rel="noreferrer noopener">Qualcomm Takeover Of Intel Is &#8216;Logically Unlikely&#8217; In Face Of Regulatory Challenges, Analyst Says</a></strong></li>
</ul>


Equities

Small Cap

Movers

MULN

Mullen Automotive's Bollinger Motors Powers Up: First Customer-Ready B4 Electric Truck Rolls Off The Line In Michigan

<p>Melius Research  analyst Karen Short   initiates coverage on Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) with a Hold rating and announces Price Target of $17.</p>


Melius Research Initiates Coverage On Grocery Outlet Holding with Hold Rating, Announces Price Target of $17

<p>HC Wainwright &amp; Co.  analyst Emily Bodnar   reiterates Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) with a Neutral and maintains $6 price target.</p>


VTYX

HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target

ORGS

Orgenesis shares are trading lower after the company announced a 1-for-10 reverse stock split.

<p>HC Wainwright &amp; Co.  analyst Emily Bodnar   reiterates Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) with a Buy and maintains $6 price target.</p>


CNTX

HC Wainwright & Co. Reiterates Buy on Context Therapeutics, Maintains $6 Price Target

<p>Baird  analyst Brian Skorney   maintains Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) with a Outperform and raises the price target from $58 to $60.</p>


BHVN

Baird Maintains Outperform on Biohaven, Raises Price Target to $60

CDT Insider Sentiment June 2024: Keep Your Seatbelt Fastened

ASCO Annual Meeting 2024: Breakthrough Treatments Hint At Renewed Hope For Patients And Investors

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Telemedicine stocks could do no wrong during the pandemic.</p>



<p>With millions on lockdown and still&nbsp;in need of&nbsp;medical care, telemedicine stocks,&nbsp;like&nbsp;<strong>Teledoc Health</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)&nbsp;ran from about $80 to a high of $288.80.&nbsp;</p>



<p>At the time, with the pandemic showing no signs of cooling,&nbsp;<a target="_blank" href="https://www.mckinsey.com/industries/healthcare/our-insights/telehealth-a-quarter-trillion-dollar-post-covid-19-reality">analysts at McKinsey</a>&nbsp;estimated &ldquo;that up to $250 billion, or 20%&nbsp;of all Medicare, Medicaid, and commercial outpatient, office, and home health&nbsp;spend could be done&nbsp;virtually.&rdquo;&nbsp;</p>



<p>The Trump Administration signed an executive order to extend telehealth services&nbsp;offered&nbsp;to Medicare beneficiaries.&nbsp;And demand for telehealth exploded&nbsp;38x&nbsp;higher than before the pandemic, added McKinsey.</p>



<p>Even venture capital investments in telemedicine tripled at the time.</p>



<p>And then it was all over. Once the crisis ended, so did the massive run in telemedicine stocks. TDOC, for one, now trades at about $8 a share.&nbsp;</p>



<p>However, while many are&nbsp;now&nbsp;well off their highs, don&rsquo;t write them off just yet. With patients still using telemedicine for mental health care, prescription refills, obesity treatment updates, etc. there&rsquo;s still a good deal of opportunity in telemedicine stocks.</p>



<h2><strong>Hims&nbsp;&amp; Hers Health (HIMS)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/hims-stock-1-300x169.jpg" alt="The logo for Hims &amp; Hers (HIMS) displayed on a smartphone screen."><div>Source: Lori Butcher / Shutterstock.com</div></div><p><strong>Hims&nbsp;&amp; Hers Health</strong>&nbsp;(NYSE:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/hims-stock-quote/">HIMS</a></strong>) has been one of the most explosive telehealth stocks on the market.</p>



<p>Since bottoming out at around $6 in late 2023, it rallied to a high of $26. Now&nbsp;back&nbsp;to $17.56 thanks to the broad market pullback, it&rsquo;s a buy on weakness.</p>



<p>For one, the company will offer a GLP-1 injection that competes with&nbsp;<strong>Novo Nordisk&rsquo;s</strong>&nbsp;(NYSE:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a></strong>) Wegovy and Ozempic. &ldquo;Hims said its treatment uses the same active ingredient as Ozempic and Wegovy, the latter of which costs $1,350 per month without insurance,&rdquo;&nbsp;<a target="_blank" href="https://www.forbes.com/sites/antoniopequenoiv/2024/05/20/hims--hers-stock-hits-3-year-high-after-announcing-199-weight-loss-alternative-to-wegovy/">added Forbes.com</a>.</p>



<p>Two,&nbsp;while the company did come under fire for allegedly referring to its GLP-1 as Mounjaro and Zepbound,&nbsp;<strong><a target="_blank" href="https://seekingalpha.com/news/4117935-hims-stock-defended-lilly-fights-compounded-glp-1s">Bank of America</a></strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/bac-stock-quote/"><strong>BAC</strong></a>) says HIMS isn&rsquo;t making any misleading claims.&nbsp;</p>



<p>Three, earnings are expected to be strong after the closing bell today. The consensus earnings per share estimate is 13 cents, which would be 533% year-over-year growth. The revenue estimate is about $301.6 million, which would be 45% year-over-year growth.&nbsp;</p>



<p>Again, I&rsquo;d use recent weakness as a reason to buy.</p>



<h2><strong>American Well Corporation (AMWL)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/amwl-stock-1-300x169.jpg" alt="The logo for American Well (AMWL) displayed on a smartphone screen. The smartphone rests on top of a keyboard."><div>Source: Stephanie L Sanchez / Shutterstock.com</div></div><p>After slipping from about $45 to a low of $5,&nbsp;<strong>American Well</strong>&nbsp;(NYSE:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/amwl-stock-quote/">AMWL</a></strong>)&nbsp;is showing&nbsp;signs of life again. Last trading at under $10, AMWL just posted better-than-expected earnings.</p>



<p>While it did post an EPS loss of $3.36, it still beat estimates by 54 cents.&nbsp;Revenue of $62.8 million, up 0.6% year over year beat by $1.19 million. Better, the company issued slightly-&nbsp;improved guidance.&nbsp;It now expects to post an adjusted EBITDA loss of between $145 million and $150 million instead&nbsp;of a loss&nbsp;of $155 million to $160 million.</p>



<p>It&rsquo;s nothing to write home about, but it shows some progress.&nbsp;</p>



<p>Helping,&nbsp;analysts at TD Cowen just&nbsp;<a target="_blank" href="https://www.streetinsider.com/Analyst+Comments/American+Well+Corp.+%28AMWL%29+PT+Raised+to+%2412+at+TD+Cowen/23537454.html">raised its price target</a>&nbsp;to $12 from $2 with a hold rating. Stifel also raised its price target to $9 from $2 with a hold rating, noting that 2024 guidance &ldquo;looks achievable,&rdquo;&nbsp;<a target="_blank" href="https://thefly.com/news.php?symbol=WELL">as&nbsp;noted&nbsp;by TheFly.com</a>.</p>



<h2><strong>Global X Telemedicine &amp; Digital Health ETF (EDOC)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/pill-bottle-biopharma-biotech-1600-300x169.jpg" alt="Brown glass pill bottle on its side showing white pills inside, with other pill bottles behind it representing MACK stock."><div>Source: shutterstock.com/Champhei</div></div><p>Or, if you&rsquo;d&nbsp;rather&nbsp;diversify with 41 telemedicine-related stocks at less than $9 a share, there&rsquo;s the&nbsp;<strong>Global X Telemedicine &amp; Digital Health ETF</strong>&nbsp;(NASDAQ:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/edoc-stock-quote/">EDOC</a></strong>).</p>



<p>With an expense ratio of 0.68%, the ETF invests in&nbsp;companies involved with&nbsp;telemedicine, healthcare analytics, connected health devices&nbsp;and&nbsp;digitization.&nbsp;Some of its top holdings include&nbsp;<strong>Resmed</strong>&nbsp;(NYSE:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/rmd-stock-quote/">RMD</a></strong>),&nbsp;<strong>Insulet</strong>(NASDAQ:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/podd-stock-quote/">PODD</a></strong>),&nbsp;<strong>Doximity</strong>&nbsp;(NYSE:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/docs-stock-quote/">DOCS</a></strong>)&nbsp;and&nbsp;<strong>Tandem Diabetes&nbsp;</strong>(NASDAQ:<strong><a target="_blank" href="https://investorplace.com/stock-quotes/tndm-stock-quote/">TNDM</a></strong>).</p>



<p>Technically, the EDOC ETF has been bouncing around in a tight channel between $8.50 and $9.50 for most of the year. Eventually, I&rsquo;d like to see it break out with an initial test of $10.25.</p>



<p><em>On the&nbsp;date of publication, Ian Cooper&nbsp;did not have (either&nbsp;directly or indirectly) any positions in the securities mentioned.&nbsp;The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a target="_blank" href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>



<p><em>On the&nbsp;date of publication, the responsible editor did not have (either&nbsp;directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/08/3-telemedicine-stocks-poised-for-possible-healthcare-evolution/">3 Telemedicine Stocks Poised for Possible Healthcare Evolution</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Global X Telemedicine & Digital Health ETF

Overview

Global X Telemedicine & Digital Health ETF (NASDAQ:EDOC), Quote.Headers.trade-ideas